Black Diamond Therapeutics Past Earnings Performance
Past criteria checks 0/6
Black Diamond Therapeutics's earnings have been declining at an average annual rate of -25.3%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-25.3%
Earnings growth rate
33.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -70.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31
Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01
Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23Revenue & Expenses BreakdownBeta
How Black Diamond Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -82 | 27 | 59 |
| 30 Sep 23 | 0 | -84 | 29 | 59 |
| 30 Jun 23 | 0 | -83 | 27 | 58 |
| 31 Mar 23 | 0 | -87 | 27 | 61 |
| 31 Dec 22 | 0 | -91 | 28 | 64 |
| 30 Sep 22 | 0 | -96 | 28 | 69 |
| 30 Jun 22 | 0 | -109 | 29 | 81 |
| 31 Mar 22 | 0 | -121 | 30 | 92 |
| 31 Dec 21 | 0 | -126 | 30 | 97 |
| 30 Sep 21 | 0 | -122 | 29 | 95 |
| 30 Jun 21 | 0 | -105 | 27 | 80 |
| 31 Mar 21 | 0 | -85 | 24 | 64 |
| 31 Dec 20 | 0 | -67 | 21 | 48 |
| 30 Sep 20 | 0 | -55 | 19 | 38 |
| 30 Jun 20 | 0 | -46 | 16 | 31 |
| 31 Mar 20 | 0 | -44 | 12 | 26 |
| 31 Dec 19 | 0 | -35 | 8 | 22 |
| 30 Sep 19 | 0 | -28 | 5 | 17 |
| 30 Jun 19 | 0 | -22 | 4 | 13 |
| 31 Mar 19 | 0 | -11 | 2 | 8 |
| 31 Dec 18 | 0 | -9 | 2 | 7 |
Quality Earnings: BDTX is currently unprofitable.
Growing Profit Margin: BDTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BDTX is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare BDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BDTX has a negative Return on Equity (-70.62%), as it is currently unprofitable.